The RETREAT-FRAIL trial was a multicenter, randomized, controlled trial in France in nursing home residents aged 80 years and older with frailty, systolic blood pressure below 130 mm Hg, and use of at least two antihypertensive medications.[1][2][4] Patients were assigned in a 1:1 ratio to the tapering group or to the standard care group.[1] The average number of antihypertensives decreased in the reduction group from 2.6±0.7 to 1.5±1.1 and in the control group from 2.5±0.7 to 2.0±1.1.[1] The primary outcome—all-cause mortality—occurred in 61.7% of patients in the reduction group (326 of 529) and 60.2% in the control group (313 of 520), with an adjusted hazard ratio of 1.02 (95% CI 0.86–1.21; P=0.78).[1] Median follow-up was 38.4 months.[1] Secondary outcomes, including major cardiovascular events and functional capacity, were similar between groups.[2] Reduction of antihypertensive treatment had no significant effect on mortality.[1][2]